First In-Body CRISPR Therapy Nears FDA Approval
Quick Facts
What Makes In Vivo CRISPR Gene Editing Different From Earlier Therapies?
Nature reports that a new CRISPR therapy is poised to gain the first FDA approval to alter genes inside the body. The only CRISPR-based medicine approved in the US so far, Casgevy for sickle cell disease and transfusion-dependent beta thalassemia, is an ex vivo therapy: a patient's blood stem cells are removed, edited in the laboratory and reinfused after conditioning chemotherapy.
In vivo approaches skip those steps. The editing components, often a guide RNA and a messenger RNA encoding an editing enzyme packaged in lipid nanoparticles, are infused and taken up mainly by the liver. This could allow a one-time treatment without cell harvesting or myeloablative conditioning, making gene editing more practical for many more patients.
What Are the Safety Questions for Editing Genes Inside the Body?
Because a DNA edit is permanent, regulators and researchers focus on specificity and long-term follow-up. Off-target editing, unintended changes at the intended site and immune responses to the delivery vehicle or editing enzyme are all monitored. Liver enzyme elevations and infusion-related reactions have been reported with lipid nanoparticle delivery in the field, and gene therapy safety has drawn scrutiny following serious adverse events in some clinical programs.
Regulators typically require extended follow-up, often up to 15 years, for gene-editing products. A first approval would set precedents for trial design, manufacturing quality and post-marketing surveillance that will shape later therapies for cardiovascular, metabolic and rare genetic diseases.
Which Diseases Could Benefit From In-Body Gene Editing?
Because lipid nanoparticles preferentially reach the liver, early programs concentrate on diseases driven by liver-produced proteins. Examples under clinical investigation across the field include transthyretin amyloidosis, hereditary angioedema and inherited lipid disorders. Personalized base-editing treatment of an infant with a rare metabolic disease, reported in 2025, showed that bespoke in vivo editing is feasible, although it also highlighted the cost and complexity of individualized therapies.
Access and affordability will be major hurdles. One-time gene therapies often carry very high list prices, and health systems are testing outcomes-based payment models. Patients considering gene editing should seek care at experienced centers and ask about long-term monitoring requirements.
Frequently Asked Questions
According to Nature, a first approval of an in vivo CRISPR therapy by the FDA is anticipated but not yet final. The currently approved CRISPR therapy, Casgevy, edits cells outside the body.
Generally no. DNA edits are intended to be permanent, which is why long-term follow-up and careful assessment of off-target effects are required.
Eligibility depends on the specific therapy and approved indication. Early candidates are people with genetic diseases driven by liver-expressed genes. A genetics specialist can advise on trials and approved options.
References
- Nature. New CRISPR therapy is poised to gain first FDA approval to alter genes inside the body. November 2026.
- U.S. Food and Drug Administration. FDA approves first gene therapies to treat patients with sickle cell disease (Casgevy). December 2023.
- U.S. Food and Drug Administration. Long Term Follow-Up After Administration of Human Gene Therapy Products: guidance for industry.